Furiex Pharmaceuticals, Inc. Confirms Takeda Global Research & Development Center, Inc.'s Announcement on the Acceptance of the EMA Submissions for Two Fixed-Dose Alogliptin Combination Therapies for the Treatment of Type 2 Diabetes

MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Global Research & Development Centre (Europe) Ltd. received confirmation from the European Medicines Agency (EMA) of the acceptance of submissions of Marketing Authorization Applications (MAAs) for alogliptin and pioglitazone combined in a single tablet and alogliptin and metformin combined in a single tablet. The EMA has confirmed that these submissions have been validated for assessment.